Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

Inclusion criteria: * Subjects with a diagnosis of complicated skin and skin-structure infections (cSSTI) defined as infection normally requiring surgical/local debridement of sufficient severity to warrant hospitalization and intravenous antimicrobial treatment * Infection to be due to Gram-positive bacteria * Hospitalized subjects * Written informed consent * Female patients of childbearing potential must have a negative pregnancy test urine or serum at baseline and must use effective contraception throughout the study period. Exclusion criteria: * Complicated skin and skin-structure infections of the following categories: * Infected burns * Severely impaired arterial blood supply * Decubitus ulcers * Infected diabetic foot ulcers associated with osteomyelitis * Infected human or animal bites * Perirectal abscess * Necrotising fasciitis or gangrene * Infections expected to require more than 14 days of intravenous antimicrobial therapy * Skin and/or skin structure infection that can be treated by surgery alone * Infections associated with a permanent prosthetic device that will not be removed within 2 days of study enrollment * Uncomplicated skin or soft tissue infection * Documented bacteremia at baseline * Concomitant infection nearby the site of infection at baseline, potentially interfering with the evaluations * Hospitalization for conditions related to rhabdomyolysis * Human immunodeficiency virus (HIV) with cluster of differentiation (CD) \< 200 or \< 14% * Immune function alterations * Lack of sufficient purulent material for culture and Gram test * Systemic or local antibiotic administration with known anti-Gram positive activity in the preceding 48 hours * Complicated skin and soft tissue infections (cSSTI) known or believed to be related to fungal, parasitic or viral infection * Pneumonia * Local or systemic known or suspected allergy to daptomycin * Creatinine clearance \< 30 mL/min * Severe liver damage (Child-Pugh class C) or Alanine transaminase (ALT) and/or Aspartate aminotransferase (AST) \> 3 x Upper limit of normal (ULN) and/or bilirubin \> 1.5 x ULN * Use of any experimental drugs in the preceding 30 days * Severe medical conditions that in the investigator's opinion could counter indicate participation in the study